AGC Biologics is part of AGC Inc.
The AGC Group is a global business conglomerate with over 186 companies and net sales of over $13 billion during FY2025.
Benefits for AGC Biologics Customers:
- Financial stability and backing of a global organization
- Long-term vision and strategic plan for AGC Biologics
- Access to capital to expand global capabilities and capacity
Our History
In December 2016, CMC Biologics announced that all of its shares were being acquired by AGC Asahi Glass (AGC), a Japanese-based manufacturer of glass, chemicals, and high-tech materials.
AGC Biologics was founded in January 2018 in Bothell, Washington, U.S.A., as a convergence of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH (Heidelberg, Germany), and CMC Biologics to form a global CDMO focused on offering microbial and mammalian capabilities, supporting early-phase, late-phase, and commercial production needs, at small and large scales.
We have since acquired additional facilities and companies around the world, expanding our offerings and creating a strong global network of manufacturing sites stretching across three continents.
Today, AGC Biologics provides world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells.
Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Bothell, Washington; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; as well as Chiba and Yokohama, Japan.
